Myeloproliferative neoplasm

• Proinflammatory and prothrombotic conditions in JAK2V617F-positive MPN: a case of Lemierre's syndrome in essential thrombocythemia
• Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
• Adult skull bone marrow is an expanding and resilient haematopoietic reservoir
• Distinctive patterns of sequential platelet counts following blunt traumatic brain injury predict outcomes
• Tyrosine Kinase Inhibitor-induced Cerebrovascular Occlusion Presenting with Moyamoya Disease-like Stenosis of the Circle of Willis
• IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
• Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas
• General anesthesia with nerve blocks for a patient with femoral fracture and essential thrombocythemia: a case report

Myeloproliferative neoplasm (MPN) is a group of rare blood disorders characterized by the overproduction of blood cells in the bone marrow. The three main types of MPN are polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF).

Myeloproliferative neoplasms (MPN) are characterized by uncontrolled expansion of myeloid cells, disease-related mutations in certain driver genes including JAK2, CALR, and MPL, and a substantial risk to progress to secondary acute myeloid leukemia (sAML). Although behaving as stem cell neoplasms, little is known about disease-initiating stem cells in MPN.

Young adults with MPNs have different PROs compared with middle-aged and elderly patients ¹⁾.

Aquagenic and non-aquagenic pruritus

Pruritus, especially AP, which is a major constitutional symptom observed in MPN, should be assessed in all MPN patients due to the higher symptom burden and higher risk of evolution ²⁾

The data were collected from three groups of Polycythemia Vera (PV) patients (70 people), Essential Thrombocythemia (ET) (50 people), and Primary Myelofibrosis (PMF) (103 people) by sampling for JAK2, CALR, and MPL gene mutation tests and demographic and clinical information have been collected through examination. The data were analyzed by SPSS v. 23 software and descriptive and chi-square statistical tests. The study included 223 myeloproliferative neoplasms (MPN) patients. JAK2 V617F mutation was detected mostly in PV patients and CALR and MPL mutations in ET and PMF patients and this mutation difference was significant in prognosis and disease diagnosis. An association between JAK 2 mutation and splenomegaly was also demonstrated. Considering the lack of a definitive diagnostic method in myeloproliferative disease, the results of this study showed that molecular studies, including JAK2 V617F, CALR, MPL mutations, and other hematological tests can be useful and effective in the diagnosis of MPN. In addition, it is necessary to pay attention to new diagnostic methods ³⁾.

Philadelphia-negative myeloproliferative neoplasm